Indivior Pharmaceuticals, Inc. — Form SCHEDULE 13D/A
Filed August 13, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 28/100
What the filing says
Six Oaktree-affiliated entities (Oaktree Value Opportunities Fund L.P., Oaktree London Liquid Value Opportunities Fund, Oaktree Phoenix Investment Fund L.P., Oaktree Capital Management L.P., Oaktree Fund GP I L.P., and Oaktree Capital Holdings LLC), all with Henry Orren as signatory Managing Director, executed a joint filing agreement dated August 13, 2026, to jointly file a Schedule 13D amendment regarding Indivior Pharmaceuticals. The filing contains only the joint filing agreement exhibit; no specific share counts, ownership percentages, acquisition details, or other substantive transaction terms are disclosed in this excerpt.
Why this rating
Schedule 13D amendment signals potential stake activity; however, no ownership %, share count, or transaction details provided here. Cannot assess magnitude relative to $1.8B market cap without concrete holdings data.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.